03.17.14
Very shortly after Hologic’s former president and CEO Robert Cascella found placement as board chairman at DySIS Medical Ltd., Hologic announced a grand shuffle of executives at home. The company, which makes medical technology that serves the needs of women, has appointed Eric Compton as chief operating officer (COO); appointed Claus Egstrand as senior vice president and general manager of international business; and begun a chief financial officer (CFO) search as CFO Glenn Muir prepares to retire in November.
As COO, Compton fills a newly-established role. He will be responsible for overseeing all of the Company’s commercial operations in the United States, as well as the company’s global research and development, manufacturing and service operations. Compton brings nearly 30 years of operating experience to the new COO position. He most recently served as Worldwide President of Ortho Clinical Diagnostics at Johnson & Johnson and previously held a number of senior positions at both Johnson & Johnson and Procter & Gamble. Compton is a member of the Board of Delaware Valley College and AdvaMed DX. He holds an MBA from Kennesaw State University and a BA from the University of Richmond.
Egstrand will be responsible for the company’s operations outside of the United States. Egstrand, who will be based in London, United Kingdom, previously worked in senior positions at leading international pharmaceutical and medical device companies including Merck & Co. Inc., Stryker Corporation, Pfizer Consumer Healthcare and Pharmacia Corporation. He has significant experience managing international business form his time as vice president and chief marketing officer of Europe, Middle East and Africa for Stryker’s Medsurg Europe division. Egstrand holds an MBA from the University of Copenhagen and an undergraduate business degree from Niels Brock, Copenhagen Business College.
David Harding was promoted from within, and previously served as Hologic’s group senior vice president and general manager of women’s health.
All three will report directly to Steve MacMillan, president and CEO and assume their new roles on April 14.
“I am excited about the changes announced today and am confident this new executive leadership structure will help accelerate organic growth in each of our businesses on a global basis, improve our operational and financial performance, and continue innovating to deliver the best solutions for our customers,” said MacMillan. “As I have done through the years, I love building winning teams. Both Eric and Claus have demonstrated track-records of success and are the right leaders to help take our performance to the next level.”
Glenn Muir’s retirement is well deserved—he joined the Bedford, Mass.-based company in 1988 and has served in various roles for Holigic over the years. Muir has been CFO since 1992 and executive vice president since 2000. He will remain with Hologic through November 30 to help ensure a smooth transition. Hologic’s search process for a new CFO has already begun.
“The past 25 years have been incredibly gratifying for me personally,” said Muir. “During that time Hologic has evolved from a single-product company to the world-class organization it is today. I am confident that Hologic stands poised to further our commitment of bringing improved care and early detection to patients around the world and I am proud of Hologic’s employees who have contributed so greatly to the Company’s success and believe so strongly in its mission. I look forward to helping transition the team to Hologic’s next phase of growth.”
MacMillan thanked Muir for his decades-long service.
As COO, Compton fills a newly-established role. He will be responsible for overseeing all of the Company’s commercial operations in the United States, as well as the company’s global research and development, manufacturing and service operations. Compton brings nearly 30 years of operating experience to the new COO position. He most recently served as Worldwide President of Ortho Clinical Diagnostics at Johnson & Johnson and previously held a number of senior positions at both Johnson & Johnson and Procter & Gamble. Compton is a member of the Board of Delaware Valley College and AdvaMed DX. He holds an MBA from Kennesaw State University and a BA from the University of Richmond.
Egstrand will be responsible for the company’s operations outside of the United States. Egstrand, who will be based in London, United Kingdom, previously worked in senior positions at leading international pharmaceutical and medical device companies including Merck & Co. Inc., Stryker Corporation, Pfizer Consumer Healthcare and Pharmacia Corporation. He has significant experience managing international business form his time as vice president and chief marketing officer of Europe, Middle East and Africa for Stryker’s Medsurg Europe division. Egstrand holds an MBA from the University of Copenhagen and an undergraduate business degree from Niels Brock, Copenhagen Business College.
David Harding was promoted from within, and previously served as Hologic’s group senior vice president and general manager of women’s health.
All three will report directly to Steve MacMillan, president and CEO and assume their new roles on April 14.
“I am excited about the changes announced today and am confident this new executive leadership structure will help accelerate organic growth in each of our businesses on a global basis, improve our operational and financial performance, and continue innovating to deliver the best solutions for our customers,” said MacMillan. “As I have done through the years, I love building winning teams. Both Eric and Claus have demonstrated track-records of success and are the right leaders to help take our performance to the next level.”
Glenn Muir’s retirement is well deserved—he joined the Bedford, Mass.-based company in 1988 and has served in various roles for Holigic over the years. Muir has been CFO since 1992 and executive vice president since 2000. He will remain with Hologic through November 30 to help ensure a smooth transition. Hologic’s search process for a new CFO has already begun.
“The past 25 years have been incredibly gratifying for me personally,” said Muir. “During that time Hologic has evolved from a single-product company to the world-class organization it is today. I am confident that Hologic stands poised to further our commitment of bringing improved care and early detection to patients around the world and I am proud of Hologic’s employees who have contributed so greatly to the Company’s success and believe so strongly in its mission. I look forward to helping transition the team to Hologic’s next phase of growth.”
MacMillan thanked Muir for his decades-long service.